<DOC>
	<DOCNO>NCT02922673</DOCNO>
	<brief_summary>Rationale : The last year , research focus move immunostimulatory agent order restore increase functionality immune system sepsis-induced immunoparalysis . Epidemiologic data show prehospital use low dose acetylsalicylic acid ( ASA ) associate improved outcome sepsis . Experimental data indicate ASA exert pro-inflammatory effect systemic inflammation . However , remain determined whether treatment ASA improve immune function immunoparalysis develop whether prehospital use low dose ASA prevent development immunoparalysis . In former case , ASA potential immunostimulatory therapy treat sepsis-induced immunoparalysis . In latter case , ASA may broader indication immunomodulating agent . Taken together , ASA might promise , cheap , well-known , globally available agent reduce incidence secondary infection improve patient outcome sepsis . Objective : - To determine whether acetylsalicylic acid treatment reverse endotoxin tolerance , express decrease pro-inflammatory cytokine level first second endotoxin challenge . - To determine whether acetylsalicylic acid prophylaxis prevent endotoxin tolerance , express decrease pro-inflammatory cytokine level first second endotoxin challenge . Study design : Double-blind randomized placebo-controlled pilot study 30 healthy male volunteer repeat experimental endotoxemia . All subject receive 14 day course study medication ( low-dose ASA placebo ) undergo experimental endotoxemia ( lipopolysacharide ( LPS ) , E.Coli type O113 ) day 7 day 14 . LPS administrate use initial bolus 1ng/kg follow continuous infusion 1ng/kg/hr 3 hour . Subjects randomize three study arm : 1 . Treatment group : 7 day placebo / first endotoxemia / 7 day ASA 80 mg ( load dose first day 160mg ) / second endotoxemia 2 . Prophylaxis group : 7 day ASA 80 mg ( load dose first day 160mg ) / first endotoxemia / 7 day ASA 80 mg / second endotoxemia 3 . Placebo group : 7 day placebo / first endotoxemia / 7 day placebo / second endotoxemia</brief_summary>
	<brief_title>The Effects Acetylsalicylic Acid Immunoparalysis Following Human Endotoxemia</brief_title>
	<detailed_description />
	<mesh_term>Endotoxemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Written inform consent Age ≥18 ≤35 yr Male Healthy ( confirm medical history , examination , ECG , blood sampling ) Use medication Use COXinhibitors within 6 week prior first endotoxemia day Smoking Known anaphylaxis hypersensitivity acetylsalicylic acid noninvestigational product History sign atopic syndrome ( asthma , rhinitis medication and/or eczema ) History peptic ulcer disease History sign hematological disease Thrombocytopenia ( &lt; 150*10^9/ml ) anemia ( hemoglobin &lt; 8.0 mmol/L ) History glucose6phosphate dehydrogenase deficiency History intracranial hemorrhage History , sign symptoms cardiovascular disease , particular : Previous spontaneous vagal collapse History atrial ventricular arrhythmia Cardiac conduction abnormality ECG consist 2nd degree atrioventricular block complete leave bundle branch block Hypertension ( define RR systolic &gt; 160 RR diastolic &gt; 90 ) Hypotension ( define RR systolic &lt; 100 RR diastolic &lt; 50 ) Renal impairment ( define plasma creatinine &gt; 120 μmol/l ) Liver enzyme abnormality ( 2x upper limit normal ) Medical history disease associate immune deficiency CRP &gt; 20 mg/L , WBC &gt; 12x109/L &lt; 4 x109/L clinically significant acute illness , include infection , within 4 week first endotoxemia day Previous ( participation study ) LPS administration Participation drug trial donation blood 3 month prior first endotoxemia day Any vaccination within 3 month prior first endotoxemia day end study Recent hospital admission surgery general anesthesia ( &lt; 3 month endotoxemia day ) Use recreational drug within 21 day prior first endotoxemia day Inability personally provide write informed consent ( e.g . linguistic mental reason ) and/or take part study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>human endotoxemia</keyword>
	<keyword>LPS</keyword>
	<keyword>acetylsalicylic acid</keyword>
	<keyword>placebo</keyword>
	<keyword>endotoxin tolerance</keyword>
</DOC>